Boron One Holdings Inc. heads into the final days of April with a sharp price drop, a doubling of estimated short interest, and a lending market so sparsely used it barely registers.
The week's most striking number is the 115% jump in estimated short shares since April 20. The reported short count moved from roughly 11,600 to just under 24,900 shares. That sounds dramatic — but context deflates it immediately. The float runs to around 263 million shares. The short position, even after doubling, amounts to less than 0.01% of the freely traded float. There is no meaningful short pressure here. The absolute numbers are too small to move a micro-cap with this share count.
The lending picture reinforces that read. Availability is extremely loose — the borrow market shows effectively zero constraint on new short positions. The 52-week peak for utilisation was just 36.6%, and recent readings have dropped all the way to zero. Cost-to-borrow data is stale, last recorded in early March at 1.78% — a rate that implies no real scramble for borrows. The short score of 26.4 (ranking in the 90th percentile on the short-score factor) and a days-to-cover rank in the 98th percentile look eye-catching in isolation, but they reflect the mechanics of a near-zero absolute position against a thin trading float, not a genuine crowding signal.
The price tells a more pointed story. The stock closed at CAD $0.035 on April 29, down 12.5% on the day and flat on the week — which itself reflects the recovery from an intra-week low. That 12.5% one-day drop on a penny stock with minimal short interest points to thin liquidity and fragile demand rather than any short-driven move. Peers on the ASX — TMB and WCE — fell 19% and 7% respectively on the same day, suggesting sector-wide pressure rather than anything specific to BONE.
The insider ledger is the most consistent signal in the data. Close relative Gwendalyn Fallis made four separate purchases between mid-2024 and early February 2026, accumulating 725,000 shares across that window at prices between CAD $0.04 and $0.05. The most recent transaction — 240,000 shares at $0.05 in February — was small in dollar terms (roughly USD $8,800) but continued a pattern of incremental accumulation. Executive Director James Wallis and the CEO also appear in the buy column from earlier periods. The trades are low-significance in absolute value, but the direction has been one-way across multiple years.
With the next earnings event pencilled in for May 29, the stock enters the pre-result window already at its lower end of its recent price range. The question worth watching is whether the thin liquidity and soft near-term price momentum attract any incremental selling pressure before that date — or whether the absence of any meaningful short position limits the downside velocity.
See the live data behind this article on ORTEX.
Open BONE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
